鳖甲生血丸治疗原发性骨髓纤维化患者120例临床观察

Clinical Observation on Biejia Shengxue Pill for 120 Cases of Primary Myelofibrosis

目的观察鳖甲生血丸治疗原发骨髓纤维化的临床疗效及不良反应。方法收集原发性骨髓纤维化患者120例，给予鳖甲生血丸8g，每日2～3次，口服，共治疗3个月。观察血常规，肝、脾情况，骨髓检查及不良反应。结果120例患者好转39例，进步47例，无效34例，总有效率71．67％。30例血红蛋白、白细胞、血小板减低患者治疗后血红蛋白、白细胞显著升高（P〈0．05）。白细胞、血小板计数增高的患者，治疗后血小板计数明显降低（P〈0．05）。114例脾肿大患者脾大情况治疗后与治疗前比较差异有统计学意义（P〈0．05）；81例肝肿大患者肝大情况治疗后与治疗前比较差异无统计学意义（P〉0．05）。骨髓病理活检显示治疗后骨髓纤维化程度有明显改善（P〈0．05）。120例患者中1l例出现少量皮肤出血点，7例有消化道不良反应，减量后消失。结论鳖甲生血丸治疗原发性骨髓纤维化有较好的近期疗效，无严重不良反应。

Objective To observe the therapeutic effect and adverse reactions of Biejia Shengxue Pill （Turtle Shell Blood -Engendering Pill） primary myelofibrosis Methods Totally 120 patients with primary myelofibrosis were selected and orally taken 8 g Biejia Shengxue Pill twice to three times daily for 3 months. The results of blood routine examination, liver, spleen, bone marrow examination and adverse reactions were observed. Results After treatment, there were 39 cases much improved, 47 cases improved, and 34 cases invalid, with a total effective rate of 71.67%. The counts of hemoglobin （HGB）, white blood cell （WBC） and platelet （PLT） were obviously increased in 30 patients with HGB reduction, WBC reduction and PLT reduction, especially HGB and WBC （P 〈 0. 05 ）. The PLT count was significantly decreased after treatment in patients with increased WBC and PLT （ P 〈 0.05 ）. There was a significant difference between before and after treatment in splenomegaly condition in 114 patients with spleno- megaly （ P 〈 0. 05 ）. There was no significant difference between before and after treatment in hepatomegaly in 81 patients with hepatomegaly （ P 〉 0.05 ）. The biopsy showed that myelofibrosis was significantly improved after treatment （ P 〈 0.05 ）. There were 11 patients with a few skin bleeding and 7 patients with gastrointestinal reactions but the ad- verse reactions disappeared when reducing the dosage myelofibrosis serious adverse reactions